Xenon Pharmaceuticals Inc.
Hedge Funds Holdings
Last updated:
Xenon Pharmaceuticals Inc.‘s stocks are currently a part of 131 hedge funds’ portfolios, which represents 100% of the total amount of its stocks outstanding. This makes up a total of 49.18M shares of Xenon Pharmaceuticals Inc.. Compared to the previous quarter, the number grew by 3.22% or 1.53M shares more. As for the holding position changes, 35.88% (47) of current hedge fund investors increased the number of shares held, 30.53% (40) of current holders sold a part of the shares held, and 12.21% (16) closed the holdings completely. 20 hedge funds are new holders of Xenon Pharmaceuticals Inc. stock in Q1 2022, it is 15.27% of total holders.
Hedge funds holding Xenon Pharmaceuticals (Q2 2017 – Q1 2022)
| Q2 2017 | 38 |
|---|---|
| Q3 2017 | 31 |
| Q4 2017 | 30 |
| Q1 2018 | 35 |
| Q2 2018 | 42 |
| Q3 2018 | 60 |
| Q4 2018 | 58 |
| Q1 2019 | 62 |
| Q2 2019 | 59 |
| Q3 2019 | 54 |
| Q4 2019 | 66 |
| Q1 2020 | 70 |
| Q2 2020 | 78 |
| Q3 2020 | 78 |
| Q4 2020 | 80 |
| Q1 2021 | 90 |
| Q2 2021 | 102 |
| Q3 2021 | 117 |
| Q4 2021 | 128 |
| Q1 2022 | 131 |
Hedge funds changes in Xenon Pharmaceuticals positions (Q2 2017 – Q1 2022)
| Q2 2017 | 7 | 9 | 5 | 4 | 13 |
|---|---|---|---|---|---|
| Q3 2017 | 3 | 6 | 5 | 9 | 8 |
| Q4 2017 | 5 | 8 | 3 | 6 | 8 |
| Q1 2018 | 7 | 3 | 9 | 2 | 14 |
| Q2 2018 | 13 | 9 | 8 | 6 | 6 |
| Q3 2018 | 27 | 11 | 15 | 9 | -2 |
| Q4 2018 | 12 | 23 | 6 | 13 | 4 |
| Q1 2019 | 8 | 23 | 15 | 5 | 11 |
| Q2 2019 | 8 | 18 | 12 | 10 | 11 |
| Q3 2019 | 4 | 11 | 18 | 9 | 12 |
| Q4 2019 | 15 | 19 | 14 | 3 | 15 |
| Q1 2020 | 18 | 22 | 18 | 13 | -1 |
| Q2 2020 | 19 | 25 | 10 | 11 | 13 |
| Q3 2020 | 5 | 16 | 27 | 5 | 25 |
| Q4 2020 | 11 | 24 | 21 | 8 | 16 |
| Q1 2021 | 13 | 34 | 24 | 4 | 15 |
| Q2 2021 | 16 | 29 | 31 | 4 | 22 |
| Q3 2021 | 25 | 35 | 30 | 9 | 18 |
| Q4 2021 | 35 | 51 | 27 | 23 | -8 |
| Q1 2022 | 20 | 47 | 40 | 16 | 8 |
Hedge funds changes in Xenon Pharmaceuticals stock options (Q2 2017 – Q1 2022)
| Q2 2017 | 0 | 0 |
|---|---|---|
| Q3 2017 | 0 | 0 |
| Q4 2017 | 0 | 0 |
| Q1 2018 | 0 | 0 |
| Q2 2018 | 4,000 | 0 |
| Q3 2018 | 6,000 | 0 |
| Q4 2018 | 6,000 | 0 |
| Q1 2019 | 10,000 | 0 |
| Q2 2019 | 1,000 | 0 |
| Q3 2019 | 1,000 | 0 |
| Q4 2019 | 253,000 | 0 |
| Q1 2020 | 6,000 | 0 |
| Q2 2020 | 5,000 | 0 |
| Q3 2020 | 0 | 0 |
| Q4 2020 | 3,000 | 0 |
| Q1 2021 | 3,086,000 | 0 |
| Q2 2021 | 3,864,000 | 652,000 |
| Q3 2021 | 30,363,000 | 22,302,000 |
| Q4 2021 | 6,148,000 | 4,705,000 |
| Q1 2022 | 557,000 | 5,250,000 |